XENE Stock Plummets as Xenon Pharmaceuticals Pauses Drug Trial
Xenon Pharmaceuticals (XENE) shares crashed on Friday after the biopharmaceutical firm said it has paused new patient enrollment in its clinical trials evaluating azetukalner. As investors responded to the setback involving XENE's lead drug candidate for major depressive disorder, its relative strength index (RSI) slipped into the early teens, indicating extremely oversold conditions.
Following today's decline, Xenon Pharmaceuticals stock is trading nearly 40% below its year-to-date high.
Bank of America Just Declared a 'Generational Entry Point' in U.S. Bonds. Why Investors Should Be Backing Up the Truck on Treasuries Here.
Mark Cuban Says He Was Dizzy for Months, So He Built a VR Fix That Does at Home 'Much Of What A 180k Machine' Does
JPMorgan Gives Up Forecasting Iran War Endgame as Trump Tells Reporters 'Anything Could Happen With Me'
Xenon's decision to pause enrollment in psychiatry trials stems from emerging reports of adverse neuropsychiatric side effects during patient monitoring.
The development is largely bearish for XENE shares as the company expected its flagship asset, azetukalner, to expand beyond focal onset seizures into major depressive disorder.
Instead, the announced halt on depression trials introduces significant regulatory uncertainty and potential delays.
While the drug's epilepsy applications remain on track with recent filings, any safety overhang in psychiatric indications threatens to diminish azetukalner's peak market potential.
Note that XENE now sits handily below its major moving averages (MAs), suggesting bears have firmly taken control across multiple timeframes.
For long-term investors, the selloff in Xenon Pharmaceuticals shares on Sept. 18 may still be a buying opportunity.
Safety reviews can certainly drag on for months or escalate into broader regulatory holds, leaving the biotech stock vulnerable to further downside or muted performance.
However, XENE has a solid balance sheet, and it continues to advance azetukalner's core late-stage epilepsy program as well, which remains a primary driver of future valuation.
In fact, RBC Capital Markets continues to rate Xenon at "Outperform" despite today's announcement. Analysts at the firm lowered its price objective this morning to $70, but their downwardly revised estimate still represents potential for about a 52% rally from current levels.
RBC is actually among the more conservative Wall Street firms on XENE stock now.
According to Barchart, the consensus rating on Xenon Pharmaceuticals sits at "Strong Buy," with the mean price target of about $80 indicating the biotech firm could roughly double from here.
